Rigel Pharmaceuticals (RIGL) Tops Q3 Street Views
Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) reports Q3 EPS of $0.96, versus the analyst estimate of $0.62. Revenue for the quarter was $72.3 million, which compares to the estimate of $55.78 million.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- VSE Corp. (VSEC) Reports Q3 EPS of $0.65
- MINDBODY (MB) Tops Q3 EPS by 3c
- Kirby Corp. (KEX) Tops Q3 EPS by 4c, Offers Q4 Guidance
Create E-mail Alert Related CategoriesEarnings
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!